TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cost-effectiveness of Early Surgery Versus Conservative Treatment With Optional Delayed Meniscectomy in Older Patients. A Randomized Controlled Trial.
Brief Summary: The purpose of this study is to determine the effectiveness of both arthroscopic knee surgery and physical therapy in the treatment of non-obstructive meniscal injuries in older patients.

The investigators assume equal improvement of physical function in both groups and reduced costs with conservative treatment.


Options:
A: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical
B: Arm Label: APM group; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Sham group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): APM group | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham group
C: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management
D: Arm Label: Arthroscopic Partial Meniscectomy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic Partial Meniscectomy | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: PROCEDURE; Name: Arthroscopic Partial Meniscectomy; Assigned to Arm(s): Arthroscopic Partial Meniscectomy | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial
Brief Summary: The aim of this study is to assess whether renal denervation (RD) added to usual care compared to usual care alone reduces blood pressure (BP) as determined with ambulatory BP monitoring (ABPM) after 6 months in subjects with an average day-time systolic BP of at least 135 mmHg as determined with use of ABPM, despite use of three or more BP lowering agents or with documented intolerance or contraindication for to 2 or more of the 4 major classes of antihypertensive drugs (ACEi/ARB, calcium channel blockers, betablockers and diuretics) obstructing use of 3 antihypertensives

Further aims are to assess the effect of renal denervation on the use of BP lowering agents, to explore the effect of renal denervation in strata of estimated glomerular filtration rate (eGFR) (eGFR 20-60 mL/min per 1.73m2 and eGFR\>60 mL/min per 1.73m2) and according to baseline office BP.

Randomization will be stratified by hospital and eGFR and will be at a 2:1 ratio.


Options:
A: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
B: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group
C: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation
D: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial
Brief Summary: The aim of this study is to assess whether renal denervation (RD) added to usual care compared to usual care alone reduces blood pressure (BP) as determined with ambulatory BP monitoring (ABPM) after 6 months in subjects with an average day-time systolic BP of at least 135 mmHg as determined with use of ABPM, despite use of three or more BP lowering agents or with documented intolerance or contraindication for to 2 or more of the 4 major classes of antihypertensive drugs (ACEi/ARB, calcium channel blockers, betablockers and diuretics) obstructing use of 3 antihypertensives

Further aims are to assess the effect of renal denervation on the use of BP lowering agents, to explore the effect of renal denervation in strata of estimated glomerular filtration rate (eGFR) (eGFR 20-60 mL/min per 1.73m2 and eGFR\>60 mL/min per 1.73m2) and according to baseline office BP.

Randomization will be stratified by hospital and eGFR and will be at a 2:1 ratio.


Options:
A: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A
B: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications
C: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
D: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection
Brief Summary: This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.


Options:
A: Arm Label: LDV/SOF 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 weeks, LDV/SOF 24 weeks, LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks
B: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
C: Arm Label: LDV/SOF 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 12 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 Week, LDV/SOF 8 Week, LDV/SOF+RBV 8 Week | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 8 Week
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Intervention Type: DRUG; Name: ombitasvir/paritaprevir/ritonavir; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Engaging Fathers in Home Visitation: Incorporation of a Coparenting Intervention
Brief Summary: The purpose of this study is to determine the efficacy of Family Foundations that is to be delivered concurrently with home visiting. Delivered prenatally and postnatally, Family Foundations is a coparenting prevention program for new mothers and fathers that is designed to optimize child outcomes by teaching parents how to work together in raising their child. Using a randomized clinical trial design, families will be assigned to receive Family Foundations + home visiting or home visiting alone. A comprehensive assessment is administered at baseline and then at post-intervention, and 9 and 18 months later. It is hypothesized that families receiving Family Foundations will improve in their resolving of conflict from pre-intervention through follow-up. Additional anticipated outcomes are that those receiving the intervention will have more involved fathers, mothers and fathers will report less conflict, and children will have better emotional and behavioral outcomes relative to those who receive home visiting alone.


Options:
A: Arm Label: Baby Triple P parent training group; Type: EXPERIMENTAL; Interventions: Behavioral: Baby Triple P | Arm Label: Care as usual control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Baby Triple P; Assigned to Arm(s): Baby Triple P parent training group
B: Arm Label: Immediate e-NET Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Arm Label: Wait List Control Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Intervention Type: BEHAVIORAL; Name: e-Net for Parents of Neurodiverse Children; Assigned to Arm(s): Immediate e-NET Group, Wait List Control Group
C: Arm Label: Family Foundations coparenting program; Type: EXPERIMENTAL; Interventions: Behavioral: Family Foundations coparenting program | Arm Label: Home visiting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home visiting | Intervention Type: BEHAVIORAL; Name: Family Foundations coparenting program; Assigned to Arm(s): Family Foundations coparenting program | Intervention Type: BEHAVIORAL; Name: Home visiting; Assigned to Arm(s): Home visiting
D: Arm Label: MOMCare intervention; Type: EXPERIMENTAL; Interventions: Behavioral: MOMCare | Arm Label: Care Plus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MOMCare; Assigned to Arm(s): MOMCare intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis
Brief Summary: In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear.

The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients.

Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups:

* Cystic Fibrosis participants with normal glucose tolerance
* Non-Cystic Fibrosis controls


Options:
A: Arm Label: GLP-1 Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GLP-1 | Arm Label: GIP Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GIP | Intervention Type: DRUG; Name: GLP-1; Assigned to Arm(s): GLP-1 Incretin Hormone | Intervention Type: DRUG; Name: GIP; Assigned to Arm(s): GIP Incretin Hormone
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2
C: Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin Asparte, Drug: Repaglinide | Intervention Type: DRUG; Name: Insulin Asparte; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): III
D: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: POSITIVE: PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy
Brief Summary: Primary Endpoint:

The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom onset have less stroke related disability and improved good functional outcomes as compared to those treated with best MT with respect to endpoint defined as:

• 90-day global disability assessed via the modified Rankin score (mRS), analyzed using raw mRS scores. Statistical details can be found in section 7.2.

Secondary Endpoints:

* 90-day global disability in the 6-12 hr cohort assessed via the overall distribution of mRS
* Proportion of patients with good functional recovery for the 6-12 hr cohort as defined by mRS 0-2 at 90 days
* Mortality at 30 and 90 days
* Intracranial hemorrhage with neurological deterioration (NIHSS worsening \>4) within 24 hours of randomization
* Procedure related serious adverse events (SAE's)
* Arterial revascularization measured by TICI 2b or 3 following device use


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: Group with endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rescue endovascular therapy | Arm Label: Group without endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No endovascular therapy | Intervention Type: PROCEDURE; Name: Rescue endovascular therapy; Assigned to Arm(s): Group with endovascular treatment | Intervention Type: PROCEDURE; Name: No endovascular therapy; Assigned to Arm(s): Group without endovascular treatment
C: Arm Label: Low-dose rtPA (Recruitment completed in August 2015); Type: EXPERIMENTAL; Interventions: Drug: Low-dose rtPA | Arm Label: Standard-dose rtPA (Recruitment completed in August 2015); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard-dose rtPA | Arm Label: Early intensive BP lowering; Type: EXPERIMENTAL; Interventions: Other: Intensive blood pressure (BP) lowering | Arm Label: Control / guideline-based BP management; Type: ACTIVE_COMPARATOR; Interventions: Other: BP management policies | Intervention Type: DRUG; Name: Low-dose rtPA; Assigned to Arm(s): Low-dose rtPA (Recruitment completed in August 2015) | Intervention Type: DRUG; Name: Standard-dose rtPA; Assigned to Arm(s): Standard-dose rtPA (Recruitment completed in August 2015) | Intervention Type: OTHER; Name: Intensive blood pressure (BP) lowering; Assigned to Arm(s): Early intensive BP lowering | Intervention Type: OTHER; Name: BP management policies; Assigned to Arm(s): Control / guideline-based BP management
D: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: POSITIVE: PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy
Brief Summary: Primary Endpoint:

The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom onset have less stroke related disability and improved good functional outcomes as compared to those treated with best MT with respect to endpoint defined as:

• 90-day global disability assessed via the modified Rankin score (mRS), analyzed using raw mRS scores. Statistical details can be found in section 7.2.

Secondary Endpoints:

* 90-day global disability in the 6-12 hr cohort assessed via the overall distribution of mRS
* Proportion of patients with good functional recovery for the 6-12 hr cohort as defined by mRS 0-2 at 90 days
* Mortality at 30 and 90 days
* Intracranial hemorrhage with neurological deterioration (NIHSS worsening \>4) within 24 hours of randomization
* Procedure related serious adverse events (SAE's)
* Arterial revascularization measured by TICI 2b or 3 following device use


Options:
A: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment
C: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
D: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Brief Summary: Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Soap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soap; Assigned to Arm(s): 1
B: Arm Label: RSV group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003891A | Arm Label: Boostrix group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003891A; Assigned to Arm(s): RSV group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Boostrix group
C: Arm Label: RSV cps2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV cps2 Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: RSV cps2 Vaccine; Assigned to Arm(s): RSV cps2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine; Assigned to Arm(s): Placebo
D: Arm Label: Group 1: Ad26.RSV.preF; Type: EXPERIMENTAL; Interventions: Biological: Ad26.RSV.preF | Arm Label: Group 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Ad26.RSV.preF; Assigned to Arm(s): Group 1: Ad26.RSV.preF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Placebo

Answer: C